Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
Status:
Withdrawn
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR)
inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute
respiratory distress syndrome (ALI/ARDS) in participants infected with mild to moderate
COVID-19 virus.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
Claude D. Pepper Older Americans Independence Center The Claude D. Pepper Older Americans Independence Centers